The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 488 participants.
Also called NCT05508035
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 488 participants
- Registry
-
NCT05508035
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT05508035. Randomized; double masking; primary purpose treatment. Start 2023-07-13 (actual); primary completion 2028-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
- Acronym
- CRACOVIA-HF
- Condition
- Heart Failure With Moderately Reduced Ejection Fraction
- Intervention (Drug)
- Sacubitril / Valsartan
- Intervention (Drug)
- Ramipril
- Lead sponsor
- John Paul II Hospital, Krakow
Record details
- Record id
cardio:ct-nct05508035- Content hash
87a7c8ee7e7ca685b5d40a504f8754d175fafba078b0cb663267325e31421ced